Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00282-6/fulltext